LONGEVITY with Nathalie Niddam #424: Part 2 - Follow Up To Dr. Bill Lawrence Episode: Answering More Of Your Bioregulator Questions With Nat Niddam & Erin Ryan
10 snips
Mar 27, 2026 Erin Ryan, producer and frequent collaborator who co-hosts this follow-up, helps steer a listeners' Q&A on bioregulators and peptides. They tackle cancer safety concerns, menopause and ovarian support, sourcing and quality control, and practical dosing strategies. Short, practical conversations about when to use or avoid these compounds and where to find trustworthy suppliers.
AI Snips
Chapters
Books
Transcript
Episode notes
Telomere Peptides Lack Human Cancer Evidence
- There is no clear evidence that telomere‑lengthening peptides like epitalon accelerate cancer in humans.
- Cavinson's elderly studies showed reduced mortality and mouse studies reduced HER2 tumor incidence, but human trials are lacking.
Avoid Bioregulators During Active Cancer
- Avoid bioregulators during active cancer and work with an experienced physician or your oncology team.
- Nathalie recommends caution because research is limited and the stakes in cancer care are high.
Immune Bioregulators May Restore Surveillance
- Immune bioregulators like thymus and pineal gland peptides theoretically support immune surveillance and recovery.
- There are examples of thymus and Vilon used after chemo/radiation to help immune recovery in clinical practice.
